Edesa Biotech Inc (EDSA)
4.468
+0.16
(+3.68%)
USD |
NASDAQ |
Apr 25, 16:00
4.42
-0.05
(-1.08%)
After-Hours: 20:00
Edesa Biotech SG&A Expense (Quarterly): 1.153M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.153M |
September 30, 2023 | 1.416M |
June 30, 2023 | 1.039M |
March 31, 2023 | 0.9524M |
December 31, 2022 | 1.021M |
September 30, 2022 | 1.042M |
June 30, 2022 | 1.25M |
March 31, 2022 | 1.532M |
December 31, 2021 | 1.211M |
September 30, 2021 | 1.357M |
June 30, 2021 | 1.608M |
March 31, 2021 | 1.535M |
December 31, 2020 | 1.234M |
September 30, 2020 | 0.8539M |
June 30, 2020 | 0.7331M |
March 31, 2020 | 1.114M |
December 31, 2019 | 0.6817M |
September 30, 2019 | 0.7983M |
June 30, 2019 | 0.8179M |
March 31, 2019 | 1.326M |
December 31, 2018 | 0.8828M |
September 30, 2018 | 0.6537M |
June 30, 2018 | 0.6512M |
March 31, 2018 | 0.774M |
December 31, 2017 | 0.6785M |
Date | Value |
---|---|
September 30, 2017 | 0.6308M |
June 30, 2017 | 0.6357M |
March 31, 2017 | 0.7464M |
December 31, 2016 | 0.9321M |
September 30, 2016 | 0.7276M |
June 30, 2016 | 0.7204M |
March 31, 2016 | 0.7651M |
December 31, 2015 | 1.110M |
September 30, 2015 | 0.8815M |
June 30, 2015 | 0.6182M |
March 31, 2015 | 0.7857M |
December 31, 2014 | 0.9422M |
August 31, 2014 | -0.006M |
May 31, 2014 | 0.8239M |
February 28, 2014 | 0.8533M |
November 30, 2013 | 1.200M |
August 31, 2013 | 0.0585M |
May 31, 2013 | 0.571M |
February 28, 2013 | 0.5569M |
November 30, 2012 | 0.5842M |
August 31, 2012 | 0.3718M |
May 31, 2012 | 1.215M |
February 29, 2012 | 0.9439M |
November 30, 2011 | 1.132M |
August 31, 2011 | -1.573M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.6817M
Minimum
Dec 2019
1.608M
Maximum
Jun 2021
1.124M
Average
1.114M
Median
Mar 2020
SG&A Expense (Quarterly) Benchmarks
Acasti Pharma Inc | 1.60M |
Aurinia Pharmaceuticals Inc | 50.07M |
Lexaria Bioscience Corp | 0.5672M |
Xenon Pharmaceuticals Inc | 12.62M |
ESSA Pharma Inc | 2.425M |